BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28331117)

  • 1. Comparison Between Effectiveness of 100 mg/day Sitagliptin and a Switch to Mitiglinide Calcium Hydrate/Voglibose from 50 mg/day Sitagliptin in Patients with Type 2 Diabetes.
    Arao T; Okada Y; Torimoto K; Sugai K; Otsuka T; Kurozumi A; Tanaka Y
    J UOEH; 2017; 39(1):1-9. PubMed ID: 28331117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized study.
    Osonoi T; Saito M; Tamasawa A; Ishida H; Osonoi Y
    Expert Opin Pharmacother; 2014 Jul; 15(10):1325-35. PubMed ID: 24866329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive postprandial glucose-lowering effects of mitiglinide and sitagliptin in patients with type 2 diabetes mellitus.
    Jung JA; Kaku K; Kim JH; Kim JR; Ko JW; Lee SY; Huh W
    Adv Ther; 2013 Nov; 30(11):1018-29. PubMed ID: 24249434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus.
    Ono Y; Kameda H; Cho KY
    Expert Opin Pharmacother; 2013 Mar; 14(4):361-70. PubMed ID: 23414242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-naïve Japanese patients with type 2 diabetes.
    Ohta A; Ohshige T; Sakai K; Nakamura Y; Tenjin A; Tsukiyama S; Terashima Y; Matsubara F; Kawata T; Nagai Y; Tanaka Y
    Expert Opin Pharmacother; 2013 Dec; 14(17):2315-22. PubMed ID: 24079645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of mitiglinide and sitagliptin, alone or in combination, on postprandial excursion and glycemic variability assessed by continuous glucose monitoring: a post hoc analysis with single-day treatment.
    Baek JH; Jin SM; Kaku K; Jung JA; Kim JR; Ko JW; Kim MJ; Lee SY; Huh WS; Kim JH
    Expert Opin Pharmacother; 2015 Jun; 16(8):1127-36. PubMed ID: 25881690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: a continuous glucose monitoring-based pilot study.
    Seo C; Sakamoto M; Nishimura R; Tsujino D; Ando K; Morimoto A; Utsunomiya K
    Diabetes Technol Ther; 2013 May; 15(5):378-85. PubMed ID: 23634671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tighter control of postprandial hyperglycemia with mitiglinide/voglibose fixed-dose combination in Japanese patients with type 2 diabetes mellitus.
    Inoue M
    Expert Opin Pharmacother; 2012 Nov; 13(16):2257-68. PubMed ID: 22994875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of fixed-dose mitiglinide/voglibose combination and glimepiride on vascular endothelial function and glycemic variability in patients with type 2 diabetes: A randomized controlled trial.
    Tanaka K; Okada Y; Umezu S; Hashimoto R; Tomoyose Y; Tateyama R; Hori Y; Saito M; Tokutsu A; Sonoda S; Uemura F; Kurozumi A; Tanaka Y
    J Diabetes Investig; 2024 Apr; 15(4):449-458. PubMed ID: 38149694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial.
    Fujimoto K; Shibayama Y; Yamaguchi E; Honjo S; Hamasaki A; Hamamoto Y
    J Diabetes; 2018 Aug; 10(8):675-682. PubMed ID: 29493100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).
    Sakamoto M; Nishimura R; Irako T; Tsujino D; Ando K; Utsunomiya K
    Cardiovasc Diabetol; 2012 Aug; 11():92. PubMed ID: 22867630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-Over Study Comparing Postprandial Glycemic Increase After Addition of a Fixed-Dose Mitiglinide/Voglibose Combination or a Dipeptidyl Peptidase-4 Inhibitor to Basal Insulin Therapy in Patients with Type 2 Diabetes Mellitus.
    Ihana-Sugiyama N; Yamamoto-Honda R; Sugiyama T; Tsujimoto T; Kakei M; Noda M
    Med Sci Monit Basic Res; 2017 Feb; 23():36-44. PubMed ID: 28242866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Add-on treatment with mitiglinide improves residual postprandial hyperglycemia in type 2 diabetic patients receiving the combination therapy with insulin glargine and sitagliptin.
    Murakami T; Nambu T; Kato T; Matsuda Y; Yonemitsu S; Muro S; Oki S
    Tohoku J Exp Med; 2015 Apr; 235(4):255-60. PubMed ID: 25810423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing postprandial efficacy in type 2 diabetic patients receiving mitiglinide and sitagliptin by using continuous glucose monitoring: a pilot study.
    Ando K; Nishimura R; Seo C; Tsujino D; Sakamoto M; Utsunomiya K
    Expert Opin Pharmacother; 2014 Dec; 15(17):2479-85. PubMed ID: 25327311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Glycemic Excursion Using Flash Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus Before and After Treatment with Voglibose.
    Kasthuri S; Poongothai S; Anjana RM; Selvakumar J; Muthukumar S; Kayalvizhi S; Tariq S; Honey E; Gupta PK; Venkatesan U; Mohan V
    Diabetes Technol Ther; 2021 Mar; 23(3):213-220. PubMed ID: 32916063
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of 50 mg vildagliptin twice daily vs. 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose.
    Nomoto H; Kimachi K; Miyoshi H; Kameda H; Cho KY; Nakamura A; Nagai S; Kondo T; Atsumi T
    Endocr J; 2017 Apr; 64(4):417-424. PubMed ID: 28260702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination.
    Ono Y; Kamoshima H; Nakamura A; Nomoto H
    Expert Opin Pharmacother; 2014 Sep; 15(13):1785-95. PubMed ID: 25046055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the Efficacy of Repaglinide Versus the Combination of Mitiglinide and Voglibose on Glycemic Variability in Japanese Patients with Type 2 Diabetes.
    Okada H; Tanaka M; Hasegawa G; Nakajima H; Kadono M; Okada Y; Hirata A; Oyamada H; Yamane T; Fukui M
    Curr Pharm Des; 2020; 25(43):4600-4605. PubMed ID: 31538887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of therapeutic effects between sitagliptin and voglibose both combined with sensor-augmented insulin pump in newly diagnosed type 2 diabetes].
    Shi CH; Wang L; Bai R; Wang YB; Liu D; Zhang XY; Wang H; Yang Y; Du JL
    Zhonghua Yi Xue Za Zhi; 2016 Aug; 96(32):2554-8. PubMed ID: 27596550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective, randomized, multicenter trial comparing the efficacy and safety of the concurrent use of long-acting insulin with mitiglinide or voglibose in patients with type 2 diabetes.
    Son JW; Lee IK; Woo JT; Baik SH; Jang HC; Lee KW; Cha BS; Sung YA; Park TS; Yoo SJ; Yoon KH
    Endocr J; 2015; 62(12):1049-57. PubMed ID: 26411328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.